Summit Therapeutics Inc. Cash Outflow For Leases
Summit Therapeutics Inc. (SMMT) reported Cash Outflow For Leases of GBP 358.00 thousand for the 11-month period ending 2019-12-31, per its 20-F filed 2020-04-30.
Discontinued › Notes › Leases
ifrs-full:CashOutflowForLeases · last filed 2020-04-30
| Period end | Cash Outflow For Leases 11 month | Cash Outflow For Leases 12 month |
|---|---|---|
| 2019-12-31 | 358.00K GBP 20-F · filed 2020-04-30 | |
| 2019-01-31 | 324.00K GBP 20-F · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |